Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $3 | $4 | $1 |
| % Growth | 99.1% | -5.8% | 183% | – |
| Cost of Goods Sold | $13 | $10 | $12 | $3 |
| Gross Profit | -$7 | -$7 | -$8 | -$2 |
| % Margin | -104.3% | -214.6% | -240.6% | -154.7% |
| R&D Expenses | $13 | $10 | $12 | $28 |
| G&A Expenses | $4 | $7 | $11 | $0 |
| SG&A Expenses | $4 | $7 | $11 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13 | -$10 | -$12 | $0 |
| Operating Expenses | $4 | $7 | $11 | $38 |
| Operating Income | -$11 | -$15 | -$20 | -$39 |
| % Margin | -168.7% | -440.4% | -563.3% | -3,179.3% |
| Other Income/Exp. Net | $0 | $1 | $0 | -$2 |
| Pre-Tax Income | -$11 | -$14 | -$20 | -$42 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$8 | -$30 | -$42 |
| % Margin | -162.8% | -248.8% | -851.9% | -3,372.7% |
| EPS | -1.19 | -1.93 | -3.58 | -5.47 |
| % Growth | 38.3% | 46.1% | 34.6% | – |
| EPS Diluted | -1.19 | -1.93 | -3.58 | -5.47 |
| Weighted Avg Shares Out | 9 | 9 | 8 | 8 |
| Weighted Avg Shares Out Dil | 9 | 9 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $3 | $3 | $3 |
| EBITDA | -$11 | -$12 | -$17 | -$39 |
| % Margin | -168.7% | -356.1% | -483.9% | -3,118% |